NCT01097018View on ClinicalTrials.gov

Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

468

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions
Colorectal Cancer
Interventions
DRUG

Capecitabine

1000 mg/m2 BID/ Days 1-14

DRUG

Perifosine

50 mg daily x 21 days

DRUG

Placebo

1 pill daily x 21 days

Trial Locations (65)

10016

New York

10504

Armonk

11040

New Hyde Park

11042

Great Neck

20817

Bethesda

21287

Baltimore

23230

Richmond

28204

Charlotte

29210

Columbia

30046

Lawrenceville

30060

Marietta

30076

Roswell

30341

Atlanta

30607

Athens

33021

Hollywood

33028

Pembroke Pines

33916

Fort Myers

37203

TN Oncology, Nashville

37404

Chattanooga

38120

Memphis

38801

Tupelo

39202

Jackson

43210

Columbus

44601

South Bend

45242

Cincinnati

47802

Terre Haute

48912

Lansing

58122

Fargo

58504

Bismarck

60068

Park Ridge

60467

Harvey

63110

St Louis

68510

Lincoln

73104

Oklahoma City

75230

Dallas

75231

Dallas

75246

Dallas

75702

Tyler

76104

Fort Worth

77030

Houston

77702

Beaumont

78731

Austin

79606

Abilene

79701

Midland

80218

Denver

81501

Grand Junction

87106

Albuquerque

87110

Albuquerque

89052

Henderson

89169

Las Vegas

90095

Los Angeles

90277

Redondo Beach

90813

Long Beach

91325

Northridge

91750

La Verne

91801

Alhambra

93105

Santa Barbara

93309

Bakersfield

93454

Santa Maria

98104

Seattle

99208

Spokane

06520

Yale University School of Medicine, New Haven

06902

Stamford

06708

Waterbury

07960

Morristown

Sponsors

Lead Sponsor

AEterna Zentaris
All Listed Sponsors
lead

AEterna Zentaris

INDUSTRY

NCT01097018 - Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer | Biotech Hunter | Biotech Hunter